Literature DB >> 18528420

Clinical and biological significance of RAS mutations in multiple myeloma.

W J Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, S V Rajkumar, M M Oken, R A Kyle, K J Henderson, S Van Wier, P Greipp, B Van Ness, R Fonseca.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18528420      PMCID： PMC3864109          DOI： 10.1038/leu.2008.142

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Clinical significance of TP53 mutation in myeloma.

Authors:  W J Chng; T Price-Troska; N Gonzalez-Paz; S Van Wier; S Jacobus; E Blood; K Henderson; M Oken; B Van Ness; P Greipp; S V Rajkumar; R Fonseca
Journal:  Leukemia       Date:  2007-01-11       Impact factor: 11.528

2.  The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.

Authors:  M M Oken; T Leong; R E Lenhard; P R Greipp; N E Kay; B Van Ness; R M Keimowitz; R A Kyle
Journal:  Cancer       Date:  1999-09-15       Impact factor: 6.860

3.  High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.

Authors:  S Bezieau; M C Devilder; H Avet-Loiseau; M P Mellerin; D Puthier; E Pennarun; M J Rapp; J L Harousseau; J P Moisan; R Bataille
Journal:  Hum Mutat       Date:  2001-09       Impact factor: 4.878

4.  Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.

Authors:  N Kalakonda; D G Rothwell; J H Scarffe; J D Norton
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?

Authors:  P R Greipp; M C Trendle; T Leong; M M Oken; N E Kay; B Van Ness; R A Kyle
Journal:  Leuk Lymphoma       Date:  1999-09

6.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

Authors:  Thomas Rasmussen; Michael Kuehl; Marianne Lodahl; Hans E Johnsen; Inger Marie S Dahl
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

Review 8.  Genetic events in the pathogenesis of multiple myeloma.

Authors:  W J Chng; O Glebov; P L Bergsagel; W M Kuehl
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020
  8 in total
  63 in total

Review 1.  Many multiple myelomas: making more of the molecular mayhem.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authors:  Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter Burger; Mathew J Rumizen; Klaus Podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Br J Haematol       Date:  2010-03-12       Impact factor: 6.998

Review 3.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

Review 4.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

5.  EBV-positive plasmacytoma of the submandibular gland--report of a rare case with molecular genetic characterization.

Authors:  Benedict Yan; Soo Yong Tan; Ee Xuan Yau; Siok Bian Ng; Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2011-03-26

Review 6.  Signaling Pathways and Emerging Therapies in Multiple Myeloma.

Authors:  Vijay Ramakrishnan; Anita D'Souza
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 7.  NRAS mutant melanoma: an overview for the clinician for melanoma management.

Authors:  Russell W Jenkins; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2016-02-17

8.  Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.

Authors:  C S Chim; K Y Wong
Journal:  Bone Marrow Transplant       Date:  2014-08-18       Impact factor: 5.483

9.  IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.

Authors:  Christian B Gocke; Ross McMillan; Qiuju Wang; Asma Begum; Vesselin R Penchev; Syed A Ali; Ivan Borrello; Carol Ann Huff; William Matsui
Journal:  Mol Cancer Ther       Date:  2016-08-29       Impact factor: 6.261

Review 10.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.